Topic: checkpoint inhibitors
Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.
Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.
Here’s a familiar sentence: A combo of Imfinzi and tremelimumab missed its primary endpoint. This time, it applies to a small-cell lung cancer trial.
The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.
BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.
Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.
BMS said the decision came after EU drug reviewers found it difficult to assess phase 3 trial data because of multiple protocol changes.
BMS has been waiting years to get a crack at the previously untreated NSCLC market, but the end to its waiting may finally be in sight.
Pfizer and Merck KGaA’s Bavencio has so far lagged behind its classmates, in part thanks to failed studies. This time, though, it’s turned in a win.
Roche has faced criticism that the diagnostic used to ID trial patients might have swayed Tecentriq's lung cancer results. Not so, an analysis says.